
Enablers and barriers for participating in a pragmatic clinical trial: a questionnaire and interview survey in Japan



Shigeru Koba¹, Asako Wada², Hiroki Saito², Naoaki Ichihara³, Shigeki Fujitani² 1: Department of Critical Care Medicine, Nerima Hikarigaoka Hospital, Japan 2: Department of Emergency and Critical Care Medicine, St. Marianna University School of Medicine, Japan


3: Department of Healthcare Quality Assessment, The University of Tokyo, Japan

Introduction

REMAP-CAP: A Randomised, Embedded, Multi-factorial, Adaptive Platform trial for Community-Acquired Pneumonia

- REMAP-CAP enables the assessment of multiple therapeutic strategies simultaneously across domains of community-acquired pneumonia.
- A total of 325 sites across 25 countries have participated in the trial, including 30 sites in Japan.
- REMAP-CAP contributes to evidence on multiple therapeutic options such as anticoagulation therapy, tocilizumab, and sarilumab against COVID-19.¹⁾²⁾³⁾ Thailand is currently preparing to participate in REMAP-CAP, supported by a team from Japan and Singapore.
- Four domains (Antibiotic domain, Macrolide duration domain, Mechanical ventilation domain, and anticoagulation for COVID-19 domain) are currently in place in Japan.

Flow of case registration




Online questionnaires and interviews were conducted among REMAP-CAP investigators at participating sites.

Result

Aim

What % of your colleagues in your department do you think understand REMAP-CAP eligibility, explain the study to patients, obtain consent and enter the data into EDC?

Among those who selected "less than 50%." In what aspects do you think they have little understanding?



More than half of respondents answered that less than half of their colleagues understand the research processes.





What efforts do you think should be made to improve enrollment in REMAP-CAP? (Free answer)

- I would like some kind of incentive for participating in this study, such as conference presentations, authorship etc.
- As it is difficult to enroll the first patient, I need more support to enroll the first case.
- I would like the information sharing on issues of case registration at each facility.

In Japan, the participating sites that enroll patients to REMAP-CAP receive a financial incentive for case management.

Are the REMAP-CAP case management fees at your institution appropriately utilized for the medical departments and staff who are primarily responsible for case enrollment in this study? (Answers in personal sennse)





Nearly 70% of the respondents reported inadequate returns.

Discussion

REMAP-CAP was able to enroll patients very rapidly during the pandemic. A global network of clinical trials is essential to respond to future outbreaks. We need to collaborate with many institutions to create a large network in preparation for the next pandemic. However, a gap exists between becoming a participating REMAP-CAP site and enrolling cases. In this survey, we investigated different perceptions in REMAP-CAP among physicians. Research is often an additional task for physicians working in Japanese community hospitals, and it was thought to be difficult to align themselves within departments.

Conclusion

Optimal communication with and support for participating sites were considered important in improving operations of the study. In addition, it was suggested that in a platform trial, which is perpetual by nature, it is paramount to ensure that the research work is rewarding according to the level of their contribution.

> References 2) N Engl J Med 2021; 385: 790 3) N Engl J Med 2021; 384: 1491 1) N Engl J Med 2021; 385: 777